Kos Settlement Keeps Barr’s Generic Niaspan, Advicor Off Market Until 2013
This article was originally published in The Pink Sheet Daily
Executive Summary
The generic firm’s decision to settle appears to have been influenced by a federal appeals court’s recent decision to rescind an earlier ruling on “public use” and patent invalidity in the Paxil case. Barr could enter the market before 2013 if another ANDA product launches.
You may also be interested in...
Barr To Co-Promote Kos' Anti-Cholesterol Products Under Settlement
Barr's patent litigation settlement with Kos includes a co-promotion agreement for the brand firm's cholesterol-lowering products Niaspan and Advicor
Zyprexa Patent Verdict Coming April 14
Timing of the Indianapolis court's verdict suggests the outcome could be favorable for Lilly. The announcement comes a week after a federal appeals court rescinded a ruling on a Paxil patent that could have aided generic companies' challenges to the olanzapine patent.
Barr To Co-Promote Kos' Anti-Cholesterol Products Under Settlement
Barr's patent litigation settlement with Kos includes a co-promotion agreement for the brand firm's cholesterol-lowering products Niaspan and Advicor